Journal Information
Vol. 42. Issue 3.
Pages 283-286 (July - September 2020)
Download PDF
More article options
Vol. 42. Issue 3.
Pages 283-286 (July - September 2020)
Case Report
DOI: 10.1016/j.htct.2019.07.009
Open Access
Short-term dose-escalated romiplostim for preparing an adult patient with persistent newly diagnosed primary immune thrombocytopenia for splenectomy
Nigel P. Murraya,b,
Corresponding author

Corresponding author at: Universidad Finis Terrae, Faculty of Medicine, Av Pedro de Valdivia 1509, Providencia, Santiago, Chile.
, Simona Minzera, Marco Antonio Lópeza, Lorena Muñoza
a Hospital de Carabineros de Chile, Ñuñoa, Santiago, Chile
b Faculty of Medicine, University Finis Terrae, Providencia, Santiago, Chile
Article information
Full Text
Download PDF
Full Text

Treatment of newly diagnosed primary immune thrombocytopenia (ITP) is aimed at obtaining a safe platelet count in order to prevent major bleeding with minimal side effects. Treatment is recommended for patients with a platelet count of <30,000 platelets/mm3, associated with bleeding or <20,000 platelets.1

The American Hematology Society (ASH) 2011 guidelines2 recommend oral prednisone 1 mg/kg/day for 21 days and subsequently tapered off, rather than dexamethasone 40 mg intravenous/oral for 4 days every two weeks. In case of hemorrhage, intravenous immunoglobulin (IVIG) 1gm/kg/day for two days is recommended.2 Platelet transfusions for life-threatening bleeding have a better response if used after IVIG infusion due to increased platelet survival.2 For patients who do not respond to steroids/IVIG, intravenous dexamethasone alone,1 or in combination with rituximab, is recommended.3 The combination provides a sustained response rate of 58% at six months and is superior to mono-therapy.4 Splenectomy is indicated for patients failing first- and second-line treatment.1 IVIG plus platelet transfusions may increase the platelet count sufficiently to decrease the risk of hemorrhage and permit surgery.1 The use of thrombopoietin receptor agonists (TPO-RAs) has been used in chronic ITP to increase the platelet count, permitting the splenectomy. There is little published data on the short-term use of TPO-RAs in patients refractory to the initial treatment for the subsequent splenectomy.

We present the case of a 27-year-old woman with newly diagnosed ITP who had persistent severe thrombocytopenia after treatment with steroids, intravenous immunoglobulin and rituximab; to enable the splenectomy, she was treated with short-term dose-escalated TPO-RA.

Clinical case

A 27-year-old woman presented with generalized petechiae and epistaxis at the local Emergency Service. Five months earlier, the patient had undergone a cholecystectomy and had a normal platelet count. An abdominal ultrasound did not show splenomegaly and an upper gastrointestinal (GI) endoscopy was reported to be normal and without evidence of Helicobacter pylori. There was no family, or personal, history of thrombocytopenia.

Initial blood tests showed a platelet count of 5,000/mm3, the rest of the full blood count was normal. Peripheral blood smear showed thrombocytopenia, with no platelet aggregates and normal platelet size. The liver function tests, TSH, prothrombin time and activated partial thromboplastin time were normal. The tests were negative for human immunodeficiency virus (HIV), hepatitis B and C, antinuclear antibodies, anti-DNA antibodies and endo-nuclear antibodies and the polymerase chain reaction (PCR) tests for cytomegalovirus (CMV) and Epstein-Barr virus (EBV) were negative. A CT scan of the thorax-abdomen and pelvis was normal, with no evidence of splenomegaly or lymphadenopathy.

Primary ITP was diagnosed and the treatment was started with intravenous dexamethasone 40 mg daily. On the third day, the platelet count was 4000/mm3, associated with mild macroscopic hematuria and epistaxis, for which the patient was transfused with six units of platelets and intravenous immunoglobulin at a dose of 1gm/kg/day for two days. The patient continued with 40 mg daily of intravenous dexamethasone for a total of seven days when the steroids were changed to oral prednisone at the dose of 1.5 mg/kg/day.

Three weeks later the platelet count remained below 10,000 platelets/mm3 and the hematuria continued. Weekly rituximab (375 mg/m2) for four cycles was commenced; five weeks later, the platelet count remained <20,000 platelets/mm3. Due to the lack of response, a bone marrow aspirate was performed, which showed an increased number of megakaryocytes and a very low CD20 lymphocyte count (post-rituximab).

On day 58, the patient was treated with a second cycle of IVIG, transfused with six units of platelets and transferred to our hospital.

The patient was re-assessed on arrival; on further questioning, the patient reported a self-limiting “viral illness” characterized by nausea, vomiting and diarrhea two weeks prior to the petechial rash. The patient was Cushingoid in appearance, with ecchymosis and petechial rash in the lower and upper limbs; both nasal fossa had been packed to treat the epistaxis. The platelet count was 20,000 platelets/mm3, the rest of the full blood count was normal and the peripheral blood smear showed some macro-platelets, but no other abnormalities. The presence of macro-platelets was not constant, as in only 3/23 full blood counts analyzed were macro-platelets detected. The therapy on arrival was 120 mg/day of oral prednisone (1.5 mg/kg/day) plus folic acid 5 mg/day. To prevent menstruation, the patient had been treated with an estrogen-containing (levonorgestrel) intrauterine device (IUD).

Prophylaxis with cotrimoxazol was started for the low CD20 count, along with high-dose steroids. The stool test for Helicobacter pylori was negative.

In summary, the patient was eight weeks post-diagnosis, without a response to steroids, IVIG or rituximab. Over the next two days, the platelet count decreased to 4000 platelets/mm3 and the oral steroids were decreased due to lack of response. The management plan was to proceed to splenectomy after a achieving a safe platelet count. To achieve this, romiplostim was started at a dose of 4 µg/kg/week subcutaneously and decreased to a dose of 2 µg/kg/week, in order to obtain a platelet count of >100,000 platelets/mm3. Daily platelet counts were taken, at one, two and three weeks after starting romiplostim; the platelet counts were 32,000, 56,000 and 112,000 platelets/mm3 with a dose of 4, 6 and 8 µg/kg/week, respectively. Laparoscopic splenectomy was performed without excessive hemorrhage or adverse effects.

The platelet counts were 320,000 platelets/mm3, 636,000 platelets/mm3 and 1,320.000 platelets/mm3 at 24 h, 5 and ten days post-splenectomy, respectively. Thrombo-prophylaxis with low molecular weight heparin and aspirin 100 mg/day were started at 24 h post-surgery. Over the next three weeks, the platelet count decreased to normal, and steroids were decreased until they were discontinued. Six months later, the patient retains a normal platelet count and has no need for steroids.


The sequence of treatment in patients not responding to first-line treatment is not well defined in ITP. Failure to respond to steroids, immunoglobulins and rituximab, as a monotherapy or in combination, and a persistent platelet count of <5,000/mm3 presents a treatment dilemma. Splenectomy is the treatment of choice for these patients, although an International Consensus recommended deferring splenectomy until the chronic phase of ITP.5

In patients with thrombocytopenia, it is necessary to determine whether the low platelet count is a result of hypo-production or hyper-destruction. Hypo-production is seen in the inherited thrombocytopenia, infiltration of the bone marrow, aplastic anemia or post-chemotherapy, while hyper-destruction is seen in ITP, disseminated intra-vascular coagulopathy and thrombotic thrombocytopenic purpura. The presence of macro-platelets and higher mean platelet volume (MPV) and distribution width (PDW), measured by automated blood analyzers, are associated with hyper-destruction. The MPV and PDW vary according to the analyzer used; the Sysmex XN1000® analyzer, used at our hospital does not calculate these parameters with <10,000 platelets/mm3.

The absence of macro-platelets may be explained as follows: in the acute phase of ITP, the hyper-destruction of platelets is greater and, as such, macro-platelets are detected. With treatment, the decrease in hyper-destruction may result in more normal-sized platelets. Autoantibodies in ITP patients also inhibit platelet production by affecting megakaryocyte production and maturation, resulting in normal or suppressed platelet production with normalization of the platelet size.6 The use of platelet parameters obtained on automated analyzers in the evaluation of suspected ITP is not recommended.2

In this clinical case, the lack of family history, a previously normal platelet count, normal coagulation tests and later bone marrow aspiration were consistent with ITP.

Romiplostim, a TPO-RA, is started at a dose of 1 µg/kg/week, adjusting the dose according to the response, which generally requires between 7–15 days. It is used as long-term maintenance therapy in persistent/chronic ITP, with little reported evidence on its use in the short term to improve the platelet count prior to splenectomy. In 31 adult patients with persistent or chronic ITP treated with TPO-RAs prior to splenectomy, there was a 77% response rate. Median platelet counts increased from 11,000/mm3 to 114,000 platelets/mm3, although it was necessary to maintain treatment with steroids and/or intravenous immunoglobulins in 61% of the cases. This permitted splenectomy in 94% of the cases, although the authors reported that an increased risk of thromboembolic events post-splenectomy could not be ruled out.7

An escalated dose of romiplostim has been reported in a small case series with eight patients, who failed to respond to steroids and IVIG, and were started at a dose of 3 µg/kg per week, reaching a dose of 6–9 µg/kg/week, and achieving >30,000 platelets/mm3 within two weeks.8 Using a higher initial dose, the time to achieve >30,000 platelets/mm3 was shorter and the response rate higher.9 Management of refractory ITP remains a challenge and the optimal sequence of treatment is not known, nor is the role of the combination therapy well defined. After failing second-line therapy, the use of a TPO-RA at an escalated dose was proposed. No side effects from the dosage regime were recorded and within three weeks the platelet count was sufficient to proceed to splenectomy.

Reactive post-splenectomy thrombocytosis is reported in approximately 80% of the cases and may reach extreme levels in some 20% of the patients.9 The use of TPO-RAs is also reported to be associated with thrombosis due to thrombocytosis.10 In this report, the platelet count reached 1,300,000 platelets/mm3 ten days post-surgery. Thrombo-prophylaxis was started 24 h after surgery, with a combination of low molecular weight heparin and aspirin 100 mg/day, as has been suggested.9

With romiplostim, the platelet count increases in a dose-dependent fashion, however its pharmaco-kinetics are non-linear and there is significant patient response variation, despite its weight-based dosing.10 Suspension of the drug 7–10 days prior to splenectomy is suggested to avoid postsurgical thrombocytosis,10 but the data on the temporal relationship between romiplostim administration and extreme thrombocytosis post-splenectomy (four days in our report) is minimal.

In the post-surgery, no further romiplostim was necessary and steroids were slowly tapered off; six months post-surgery the patient maintained a platelet count of between 200,000/mm3 and 250,000/mm3 and is off steroid therapy.

Concerning the initial management of the patient, seven days of intravenous dexamethasone and then oral prednisone is not a suggested schedule and it could be argued that mild macroscopic hematuria and epistaxis are not life-threatening events and that platelet transfusions and intravenous immunoglobulin are not indicated. Local treatment of the cause of epistaxis may have been sufficient. Rituximab, which causes long-term immunosuppression, was used early in this case; the time response for steroids is from 3 to 30 days and thus, the period for an expected response to steroids had not been completed. This emphasizes that an experienced medical team should manage patients with severe thrombocytopenia or that they be transferred early to a medical center with the appropriate specialists.


Short-term escalated dose romiplostim may improve platelet counts sufficiently to perform splenectomy, without an increased risk of bleeding in patients who have failed previous treatments. It is crucial to closely monitor platelet counts post-splenectomy, administer thrombo-prophylaxis and antiplatelet therapy, if necessary. For extreme thrombocytosis, platelet-apheresis may be warranted and thus, hospitalization and close monitoring are essential. Although TPO-RAs are efficacious, they are costly and in the local environment, this may be prohibitive.

Conflict of interest

The authors declare no conflicts of interest.

R.A. Ribeiro, A.S. Neto, A.S. Furtado, L.L. Albuquerque, M.S. Kubrusy, E.S. Kubrusly.
Proposal of treatment algorithm for immune thrombocytopenia in adult patients of a hematology service at a referral centre in Northeastern Brazil.
Hematol Transfus Cell Ther, (2019),
C. Nuenert, W. Lim, M. Crowther, A. Cohen, L. Solberg Jr, M.A. Crowther.
The American Society of Hematology 2011 evidence based practice guidelines for immune thrombocytopenia.
Blood, 117 (2011), pp. 4190-4207
V.L. Patel, M. Mahevas, S.Y. Lee, R. Stasi, S. Cunningham-Rundles, B. Godeau, et al.
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.
Blood, 119 (2012), pp. 5989-5995
J. Wang, Y.L. Chong Wang, Y. Zhang, C. Gao, H. Lang, X. Chen.
Efficacy and safety of the combination treatment of rituximab and dexamethasone for adults with primary immune thrombocytopenia (ITP): a meta-analysis.
D. Provan, R. Stasi, A.C. Newland, V.S. Blanchette, P. Bolton-Maggs, J.B. Bussel, et al.
International consensus report on the investigation and management of primary immune thrombocytopenia.
Blood, 115 (2010), pp. 168-186
M. Negash, A. Tsegaye, A.G. Medhin.
Diagnostic predictive value of platelet indices for discriminating hypo productive versus immune thrombocytopenia purpura in patients attending a tertiary care teaching hospital in Addis Ababa, Ethiopia.
BMC Hematol, 16 (2016), pp. 18
F. Zaja, W. Barcellini, S. Cantoni, M. Carpenedo, G. Caparrotti, V. Carrai, et al.
Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Am J Hematol, 91 (2016), pp. E293-E295
A. Contis, E. Lazaro, C. Greib, J.L. Pellegrin, J.F. Viallard.
Romiplostim as early treatment for refractory primary immune thrombocytopenia.
Int J Hematol, 98 (2013), pp. 520-524
J. Zimmerman, K.J. Norsworhty, R. Brodsky.
Balencing therapy with thrombopoietin receptor agonists and splenectomy in refractory immune thrombocytopenic purpura: a case of postsplenectomy thrombocytosis requiring plateletpheresis.
Case Rep Hematol, 2016 (2016),
B.B. Yang, S. Doshi, K. Arkam, J. Franklin, A.T. Chow.
Development of romiplastin for treatment of primary immune thrombocytopenia from a pharmacokinetic and pharmacodynamics perspective.
Clin Pharmacokinet, 55 (2016), pp. 1045-1058
Copyright © 2019. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular
Hematology, Transfusion and Cell Therapy

Subscribe to our newsletter

Article options
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.